EN DE
Watch PT Brigit Biofarmaka Technologi Tbk for free: we tell you when fair value or trend changes.
Data-driven stock valuation

PT Brigit Biofarmaka Technologi Tbk (OBAT) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of PT Brigit Biofarmaka Technologi Tbk stock IDR 702, price IDR 244, upside +187.7%, quality 58 out of 100. Rating: strongly undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive ID

PB PT Brigit Biofarmaka Technologi Tbk logo Thin data Nov 14, 2026

PT Brigit Biofarmaka Technologi Tbk

OBAT · JK

Cheap (65% below fair value) and solid company, but falling price: meets 2 of 3 rules.

Get notified free when this changes
Fair value 701.90 IDR · Strongly undervalued 
Low debt 
Ranks above peers (9/12) 
Even on cautious assumptions the value is 31% above the price (320.27 IDR). 
Quality 58/100 
Expensive Growth (revenue YoY +32.7 %/yr in IDR) 
Thin margins · 7.1% net margin (TTM) 
Moderate moat 61/100 · thin data
Changed on Oct 25: IDR 432.56 → IDR 701.90 
Falling price (downtrend) 
Thin data 
⚠ Small free float
Watch PT Brigit Biofarmaka Technologi Tbk for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

833.48 IDR 193.00 IDR Fair Value 701.90 IDR Jan 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

22‑month range 193.00 IDR – 833.48 IDR · fair‑value band 320.27 IDR – 877.38 IDR · the 244.00 IDR price screens below the 701.90 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow PT Brigit Biofarmaka Technologi Tbk in your weekly email

Every Wednesday you see whether PT Brigit Biofarmaka Technologi Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Brigit Biofarmaka Technologi Tbk provides manufacturing services for herbal medicine, herbal honey, skincare, cosmetics, botanical tea, and functional powdered drinks in Indonesia.

Show moreShow less

It also offers hair care products, including shampoo, conditioner, hair mask, hair tonic, hair oil, and hair serum and powder, as well as body moisturizer, body cleanser, facial cleanser, moisturizer, essence and serum, face mask, and personal care products.

In addition, it provides lip gloss, cushion, foundation, eyeliner, and blush on balm. The company was founded in 2015 and is based in Sukoharjo, Indonesia.

Stock analysis

PT Brigit Biofarmaka Technologi Tbk (OBAT) currently trades at 244.00 IDR, while our model-based Fair Value estimate is 701.90 IDR, implying the stock looks roughly 65% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 1,546 IDR per share, and 17 of the 22 models we run sit above the 244.00 IDR price.

Bear case: the Asset-Based group reads lowest at 72.04 IDR, and 5 of the 22 models stay below the price. Data coverage for this calculation is low.

Scenario range: 320.27 IDR (bear) to 877.38 IDR (bull), the price of 244.00 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Consumer Defensive sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

PT Brigit Biofarmaka Technologi Tbk reported revenue of 160B IDR in FY2025 versus 56.9B IDR in FY2023, a compound +67.7%/yr. Reported net income was 22.6B IDR in FY2025, compounding +37.5%/yr from FY2023.

Key figures

Market cap 172B IDR (≈ $9.4M) Micro · P/S ratio 0.97 · Dividend yield 8.0% · Net margin 7.1% · Return on equity 12.7% · Return on assets (EBIT) 40.8% (3-year average) · Operating margin 13.8% · Revenue (TTM) 173B IDR.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 61 out of 100 (low confidence).

What moves the price

The share trades about 42% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at 0% fair-value upside, at 188%, OBAT screens cheaper than that median.

Fair Value models

Bear 320.27 IDR Fair Value 701.90 IDR Bull 877.38 IDR
Price 244.00 IDR · Upside +187.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 112.21 IDR 136.46 IDR 207.76 IDR 71
EPV 339.72 IDR 375.49 IDR 404.77 IDR 71
Growth DCF 108.54 IDR 143.68 IDR 198.62 IDR 70
All 22 models by family
DCF Models
FCF DCF 112.21 IDR 136.46 IDR 207.76 IDR 71
5Y Revenue Exit 387.80 IDR 710.52 IDR 1,392 IDR 60
5Y P/E Exit 437.68 IDR 1,014 IDR 1,815 IDR 59
10Y Revenue Exit 272.97 IDR 692.53 IDR 1,008 IDR 57
10Y P/E Exit 320.27 IDR 786.30 IDR 1,586 IDR 52
Earnings-Based
Graham-Dodd 226.29 IDR 1,578 IDR 2,215 IDR 56
Lynch FV 853.04 IDR 1,219 IDR 1,584 IDR 54
PEG = 1.0 853.04 IDR 1,219 IDR 1,584 IDR 51
EPV 339.72 IDR 375.49 IDR 404.77 IDR 71
Dividend Discount
Gordon GGM 142.75 IDR 244.88 IDR 323.75 IDR 61
DDM Multi-Stage 142.75 IDR 229.49 IDR 262.88 IDR 60
Multiples
P/E Multiple 549.10 IDR 732.13 IDR 915.16 IDR 63
P/S Multiple 424.30 IDR 565.74 IDR 707.17 IDR 58
P/B Multiple 526.43 IDR 701.90 IDR 877.38 IDR 55
EV/EBIT 674.04 IDR 880.53 IDR 1,087 IDR 66
EV/Revenue 496.69 IDR 686.18 IDR 875.67 IDR 54
Asset-Based
NCAV (Graham) 47.54 IDR 72.04 IDR 90.04 IDR 54
Growth DCF
Growth DCF 108.54 IDR 143.68 IDR 198.62 IDR 70
Rev-Margin DCF 427.36 IDR 803.39 IDR 1,583 IDR 60
Economic Profit
Residual Income 174.75 IDR 220.43 IDR 322.36 IDR 67
ROIC Compounder 409.16 IDR 550.87 IDR 717.46 IDR 64
Growth Earnings
Growth-Adj P/E 1,082 IDR 1,546 IDR 2,010 IDR 60

Open the full fair value analysis →

Quality Score breakdown

Overall quality 58/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 83
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 31
Do the profits arrive as real cash?
Financial strength 84
Debt, balance sheet and risk of trouble
Investment 40
Does it invest with discipline instead of growing at any price?
Low Volatility 35
How calm the share price moves, does not count
Price momentum 24
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 11
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

Watch OBAT, get fair value alerts →

Compare PT Brigit Biofarmaka Technologi Tbk with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 663 stocks

Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 58 · Above median
Fair Value upside +187.7% · Top 25%
Profitability
Return on equity (12 months) 12.7% · Above median
Return on assets 17.3% · Top 25%
Net margin (12 months) 7.1% · Above median
Operating margin (12 months) 13.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −5.0% · Bottom 25%
Dividend yield (12 months) 8.0% · Top 25%
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Packaged Foods median · lower = cheaper

P/B 1.60× · Pricier than median
P/S (12 months) 0.99× · Pricier than median
EV/EBITDA 7.0× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 34
FUTURE (revenue growth)0 · sector 26
PAST (return on equity)51 · sector 31
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)100 · sector 54

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wilmar International Limited F34 2.90 SGD 4.94 SGD +70% vs OBAT
Inner Mongolia Yili Industrial Group 600887 ¥32.20 ¥41.84 +30% vs OBAT
The Kraft Heinz Company KHC $25.07 $29.20 +16% vs OBAT
Foshan Haitian Flavouring and Food Company 603288 ¥35.76 ¥38.07 +6% vs OBAT
General Mills, Inc GIS $35.24 $35.30 +0% vs OBAT
Danone S.A BN €70.66 €50.65 −28% vs OBAT
Nestlé S.A NESN CHF 88.12 CHF 59.51 −32% vs OBAT
Kerry Group KRZ €101.80 €60.33 −41% vs OBAT
Nestlé India Limited NESTLEIND ₹1,297 ₹724.74 −44% vs OBAT
Yihai Kerry Arawana Holdings 300999 ¥25.32 ¥12.21 −52% vs OBAT

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PT Brigit Biofarmaka Technologi Tbk: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "PT Brigit Biofarmaka Technologi Tbk Fair Value". https://www.fairvalue-calculator.com/stock/OBAT

Frequently asked questions

Is PT Brigit Biofarmaka Technologi Tbk (OBAT) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of 701.90 IDR versus a price of 244.00 IDR, about +188% upside (undervalued).
What is the fair value of OBAT?
Our model-based fair value for PT Brigit Biofarmaka Technologi Tbk is 701.90 IDR (as of Nov 14, 2026), built from audited fundamentals. The current price: 244.00 IDR.
What is the quality score of OBAT?
PT Brigit Biofarmaka Technologi Tbk has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PT Brigit Biofarmaka Technologi Tbk (OBAT)?
Our model-based price target is the fair value of 701.90 IDR (as of Nov 14, 2026) from 22 valuation models. Cautious scenario 320.27 IDR, optimistic scenario 877.38 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the PT Brigit Biofarmaka Technologi Tbk stock forecast for 2026?
Our models put fair value at 701.90 IDR, about +188% upside versus a price of 244.00 IDR (undervalued). Cautious scenario 320.27 IDR, optimistic scenario 877.38 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
PT Brigit Biofarmaka Technologi Tbk reported trailing-twelve-month revenue of about 173B IDR (latest available figure, as of Nov 14, 2026).
Does PT Brigit Biofarmaka Technologi Tbk pay a dividend?
PT Brigit Biofarmaka Technologi Tbk currently shows a dividend yield of 8.02% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
PT Brigit Biofarmaka Technologi Tbk has a dividend yield of 8.0%.
What is the intrinsic value of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT Brigit Biofarmaka Technologi Tbk it is 701.90 IDR per share (as of Nov 14, 2026), against a price of 244.00 IDR. It is the blended result of 22 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is PT Brigit Biofarmaka Technologi Tbk stock overvalued or undervalued in 2026?
As of Nov 14, 2026, OBAT trades below its calculated fair value: price 244.00 IDR, fair value 701.90 IDR, a gap of about +188% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OBAT?
No. The price is what the market pays today (244.00 IDR); the fair value is what the company's own numbers justify (701.90 IDR). For PT Brigit Biofarmaka Technologi Tbk the two are 457.90 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is PT Brigit Biofarmaka Technologi Tbk worth?
The market values PT Brigit Biofarmaka Technologi Tbk at about 172B IDR (market capitalisation, as of Nov 14, 2026). Per share that is 244.00 IDR; our models calculate a fair value of 701.90 IDR per share.
What do the bullish and bearish scenarios say about OBAT?
Our models span a range for PT Brigit Biofarmaka Technologi Tbk: cautious scenario 320.27 IDR, base 701.90 IDR, optimistic 877.38 IDR per share (as of Nov 14, 2026, price 244.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
Balance-sheet figures for PT Brigit Biofarmaka Technologi Tbk (as of Nov 14, 2026): return on equity 12.7%, debt of 0.05 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is OBAT from its 52-week high?
PT Brigit Biofarmaka Technologi Tbk trades at 244.00 IDR, about 42% below its 52-week high of 422.04 IDR and 26% above the low of 193.00 IDR (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 701.90 IDR is for.
Which stocks are comparable to PT Brigit Biofarmaka Technologi Tbk?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, Inner Mongolia Yili Industrial Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PT Brigit Biofarmaka Technologi Tbk stock attractive at the current price?
The data as of Nov 14, 2026: price 244.00 IDR, calculated fair value 701.90 IDR (+188%), Quality Score 58/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OBAT calculated?
We run PT Brigit Biofarmaka Technologi Tbk through 22 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 701.90 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. PT Brigit Biofarmaka Technologi Tbk currently trades 65% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The closing price on Nov 16, 2026 was 244.00 IDR. Our model-based fair value is 701.90 IDR, about +188% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PT Brigit Biofarmaka Technologi Tbk right now?
The price is below even our cautious bear case (320.27 IDR). The market is more pessimistic than our downside scenario. The model range is unusually wide (320.27 IDR to 877.38 IDR). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of PT Brigit Biofarmaka Technologi Tbk

How large is the market capitalisation of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The market capitalisation of PT Brigit Biofarmaka Technologi Tbk is 172B IDR (≈ $9.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The price-to-sales ratio of PT Brigit Biofarmaka Technologi Tbk is 0.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The dividend yield of PT Brigit Biofarmaka Technologi Tbk is 8.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The net margin of PT Brigit Biofarmaka Technologi Tbk is 7.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The return on equity (ROE) of PT Brigit Biofarmaka Technologi Tbk is 12.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
On an EBIT basis the return on assets of PT Brigit Biofarmaka Technologi Tbk is 40.8% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The operating margin of PT Brigit Biofarmaka Technologi Tbk is 13.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PT Brigit Biofarmaka Technologi Tbk (OBAT)?
Revenue at PT Brigit Biofarmaka Technologi Tbk is down 5.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PT Brigit Biofarmaka Technologi Tbk (OBAT)?
Earnings per share at PT Brigit Biofarmaka Technologi Tbk are down 68.7% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch PT Brigit Biofarmaka Technologi Tbk in the live analysis

One click puts PT Brigit Biofarmaka Technologi Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.